Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Share-based Compensation (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Share-based Compensation data on record, last reported at $6.4 million in Q4 2025.

  • For Q4 2025, Share-based Compensation fell 5.27% year-over-year to $6.4 million; the TTM value through Dec 2025 reached $27.6 million, down 16.32%, while the annual FY2025 figure was $27.6 million, 16.32% down from the prior year.
  • Share-based Compensation reached $6.4 million in Q4 2025 per AMLX's latest filing, down from $7.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $10.2 million in Q3 2023 and bottomed at $586000.0 in Q1 2021.
  • Average Share-based Compensation over 5 years is $6.1 million, with a median of $6.8 million recorded in 2024.
  • Peak YoY movement for Share-based Compensation: skyrocketed 768.65% in 2022, then tumbled 33.15% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $1.1 million in 2021, then skyrocketed by 458.3% to $6.1 million in 2022, then skyrocketed by 56.53% to $9.5 million in 2023, then decreased by 29.3% to $6.7 million in 2024, then fell by 5.27% to $6.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Share-based Compensation were $6.4 million in Q4 2025, $7.1 million in Q3 2025, and $7.4 million in Q2 2025.